BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Mega $3 Billion+ Deal Shapes Up for Roche to Target AD and Parkinson’s

  Roche will apply RNAfix and Shape’s AAVid technology platform to develop next-generation tissue-specific adeno-associated viruses for new gene therapies aimed at these indications.

  August 24, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Injectable Drug KORSUVA Approved to Stop the Itch for CKD Patients on Hemodialysis

  The FDA has approved the use of the injectable drug KORSUVA in treating moderate to severe pruritus in adult patients undergoing hemodialysis for chronic kidney disease.

  August 24, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  FDA

  Pfizer-BioNTech COVID-19 Vaccine Receives Full Approval – Now What?

  The new authorization is expected to be the final reassurance for many of those who had hesitated when the vaccine was approved under emergency use only.

  August 24, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Policy

  U.S. Intelligence Report on COVID-19 Origins Expected Today

  President Biden is expected to be briefed on the lab leak theory conducted over the last 90 days. Very few expect solid results, although this might provide direction for more lines of inquiry.

  August 24, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Vertex and Arbor Strike a $1.2 Billion Deal for Gene-Editing Programs

  With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.

  August 24, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  Money on the Move: August 18 – 24

  The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week.

  August 24, 2021

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Business

  Atavistik Bio Secures $60 Million to Leverage Metabolite-Protein Interactions Against Disease

  Atavistik Bio is linking a deep understanding of metabolite-protein interactions and their potential to lead to novel drugs that will restore protein function in metabolic diseases and cancers.

  August 24, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Novartis’ Kymriah Disappoints in Phase III for Aggressive B-Cell NHL

  Novartis reported that its Kymriah failed to hit its primary endpoint in the Phase III BELINDA trial in aggressive B-cell non-Hodgkin lymphoma after relapse or lack of response to first-line treatment.

  August 24, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Deals

  Working to Tackle Drug Resistance in Oncology Patients, Tyra Aims for $100 Million IPO

  Tyra Biosciences aspires to raise a $100 million IPO, according to its S-1 form filed with the U.S. Securities and Exchange commission late last week.

  August 24, 2021

   · 

  2 min read

   · 

  Ellen Bombela
• 

  Drug Development

  Theravance Drug Candidate Izencitinib Fails To Meet Primary Endpoint

  Izencitinib was generally well tolerated and its safety data were consistent with expectations, but it failed to achieve its primary endpoint. Here’s more about it.

  August 24, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN